- Home
- ELF vs LEGN Comparison
ELF vs LEGN Comparison
Compare ELF & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELF
- LEGN
- Stock Information
- Founded
- ELF 2004
- LEGN 2014
- Country
- ELF United States
- LEGN United States
- Employees
- ELF N/A
- LEGN N/A
- Industry
- ELF Package Goods/Cosmetics
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ELF Consumer Discretionary
- LEGN Health Care
- Exchange
- ELF Nasdaq
- LEGN Nasdaq
- Market Cap
- ELF 6.0B
- LEGN 5.4B
- IPO Year
- ELF 2016
- LEGN 2020
- Fundamental
- Price
- ELF $129.42
- LEGN $34.26
- Analyst Decision
- ELF Strong Buy
- LEGN Strong Buy
- Analyst Count
- ELF 16
- LEGN 12
- Target Price
- ELF $124.88
- LEGN $73.36
- AVG Volume (30 Days)
- ELF 2.5M
- LEGN 992.1K
- Earning Date
- ELF 08-06-2025
- LEGN 08-11-2025
- Dividend Yield
- ELF N/A
- LEGN N/A
- EPS Growth
- ELF N/A
- LEGN N/A
- EPS
- ELF 1.69
- LEGN N/A
- Revenue
- ELF $1,342,779,000.00
- LEGN $796,838,000.00
- Revenue This Year
- ELF $26.45
- LEGN $70.75
- Revenue Next Year
- ELF $17.58
- LEGN $52.47
- P/E Ratio
- ELF $76.88
- LEGN N/A
- Revenue Growth
- ELF 18.61
- LEGN 74.75
- 52 Week Low
- ELF $49.40
- LEGN $27.34
- 52 Week High
- ELF $159.22
- LEGN $59.62
- Technical
- Relative Strength Index (RSI)
- ELF 58.91
- LEGN 33.08
- Support Level
- ELF $112.42
- LEGN $34.48
- Resistance Level
- ELF $119.01
- LEGN $35.39
- Average True Range (ATR)
- ELF 5.16
- LEGN 1.23
- MACD
- ELF 0.81
- LEGN -0.29
- Stochastic Oscillator
- ELF 97.28
- LEGN 2.12
About ELF e.l.f. Beauty Inc.
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.